LATITUDE Phase 3 trial

June 14, 2018

Zytiga Rejected in England as First-line Treatment for Newly Diagnosed Advanced Prostate Cancer

News

Janssen’s medication Zytiga (abiraterone) was recently rejected as a first-line treatment for newly diagnosed advanced prostate cancer on the National Health Service (NHS) in England following an initial draft recommendation from the National ... Read more

February 19, 2018February 19, 2018

Health Canada Approves New Indication for Zytiga for Treatment of Hormone-Sensitive Prostate Cancer

News

Health Canada recently approved Zytiga (abiraterone acetate) in combination with prednisone and androgen deprivation therapy (ADT) for the treatment of patients with newly diagnosed, high-risk metastatic hormone-sensitive prostate cancer (mHSPC) ... Read more

February 14, 2018February 14, 2018

FDA Approves Zytiga Plus Prednisone for Earlier Form of Metastatic Prostate Cancer

News

Zytiga (abiraterone acetate) is now approved in the U.S. to treat metastatic high-risk castration-sensitive prostate cancer (CSPC) in combination with prednisone, Janssen Pharmaceutical Companies announced. The U.S. Food and Drug ... Read more

October 26, 2017

EMA’s CHMP Recommends Zytiga Combo Therapy for Certain Early-stage Prostate Cancer Patients

News

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended that the prostate cancer combo therapy Zytiga (abiraterone acetate) plus prednisone/prednisolone in combination with androgen deprivation ... Read more

June 7, 2017June 7, 2017

Adding Zytiga, Prednisone to ADT Improves Outcomes for Newly Diagnosed, High-risk Metastatic Prostate Cancer Patients

News

Newly diagnosed men with high-risk metastatic hormone-naive prostate cancer (mHNPC) lived significantly healthier, longer lives when doctors added Zytiga (abiraterone acetate) and prednisone to their androgen deprivation therapy (ADT), according to results ... Read more